Literature DB >> 31577382

Mechanistic rationale for factor XIII cotreatment in haemophilia.

Joan D Beckman1, Alisa S Wolberg2.   

Abstract

Entities:  

Year:  2019        PMID： 31577382      PMCID： PMC7032044          DOI： 10.1111/hae.13855

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  15 in total

1.  Factor XIII in the treatment of hemophilia A.

Authors:  Catherine J Rea; Jonathan H Foley; Benny Sørensen
Journal:  N Engl J Med       Date:  2012-01-19       Impact factor: 91.245

2.  The inhibiting effect of factor XIII on hyperfibrinolysis.

Authors:  Oliver M Theusinger
Journal:  Anesth Analg       Date:  2012-06       Impact factor: 5.108

3.  Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.

Authors:  J D Beckman; L A Holle; A S Wolberg
Journal:  J Thromb Haemost       Date:  2017-11-20       Impact factor: 5.824

4.  Acquired haemophilia A and concomitant factor XIII consumption.

Authors:  Jameel Abdulrehman; Brett L Houston; Hina Chaudhry; Georges-Etienne Rivard; Jerome M Teitel; Michelle Sholzberg
Journal:  Haemophilia       Date:  2019-03-07       Impact factor: 4.287

5.  In vitro factor XIII supplementation increases clot firmness in Rotation Thromboelastometry (ROTEM).

Authors:  Oliver M Theusinger; Werner Baulig; Lars M Asmis; Burkhardt Seifert; Donat R Spahn
Journal:  Thromb Haemost       Date:  2010-04-29       Impact factor: 5.249

6.  Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery.

Authors:  Yesim Dargaud; Anne Lienhart; Claude Negrier
Journal:  Blood       Date:  2010-09-01       Impact factor: 22.113

7.  Efficacy and safety of prophylactic treatment with plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency.

Authors:  C Ashley; E Chang; J Davis; A Mangione; V Frame; D J Nugent
Journal:  Haemophilia       Date:  2014-11-07       Impact factor: 4.287

8.  Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors.

Authors:  A Gringeri; K Fischer; A Karafoulidou; R Klamroth; M F López-Fernández; E Mancuso
Journal:  Haemophilia       Date:  2011-02-15       Impact factor: 4.287

9.  Challenges in diagnosis and management of acquired factor XIII (FXIII) inhibitors.

Authors:  Joan D Beckman; Raj S Kasthuri; Alisa S Wolberg; Alice D Ma
Journal:  Haemophilia       Date:  2018-08-24       Impact factor: 4.287

10.  Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α-chain crosslinking.

Authors:  James R Byrnes; Cédric Duval; Yiming Wang; Caroline E Hansen; Byungwook Ahn; Micah J Mooberry; Martha A Clark; Jill M Johnsen; Susan T Lord; Wilbur A Lam; Joost C M Meijers; Heyu Ni; Robert A S Ariëns; Alisa S Wolberg
Journal:  Blood       Date:  2015-08-31       Impact factor: 22.113
View more
  1 in total

1.  Evaluation Procoagulant Activity and Mechanism of Astragalin.

Authors:  Changqin Li; Miyun Hu; Shengjun Jiang; Zhenhua Liang; Jinmei Wang; Zhenhua Liu; Hui-Min David Wang; Wenyi Kang
Journal:  Molecules       Date:  2020-01-01       Impact factor: 4.411
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.